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1058-73 Microsimulation to Support Prosthetic Aortic Valve 
Selection
Johanna J.M. Takkenberg, John P.A. Puvimanasinghe, Marinus J.C. Eijkemans, Lex A. 
van Herwerden, Ewout W. Steyerberg, J. Dik F. Habbema, Ad J.J.C. Bogers, Erasmus 
MC, Rotterdam, The Netherlands
Background. Prognosis after aortic valve replacement (AVR) is determined by multiple
inter-related factors, and objective selection of the preferred valve substitute can be diffi-
cult. Standard statistical methods do not allow detailed insight into the factors that affect
outcome in the individual patient.
Methods. The use of a microsimulation state-transition model to predict age- and gender-
specific outcome is illustrated using meta-analyses on the occurrence of valve-related
events and outcome after AVR with different valve substitutes (bileaflet mechanical
valves (N=2986), stented bioprostheses (N=5837), allografts (N=629) and autografts
(N=380)). The microsimulation model uses the meta-analysis information to generate a
large number (10,000) of age and gender-specific life histories of patients after AVR,
allowing detailed insight into all probable outcomes after AVR for patients with this spe-
cific age and gender. The impact of valve-related events, excess mortality due to heart
valve disease, and other non-valve-related events on survival can thus be quantified.
Results. Compared to healthy age-matched people, life expectancy of patients after AVR
is markedly reduced, especially at a younger age. For a 40-year-old male patient mean
life expectancy after AVR is reduced from 35 to 19-20 years, depending on the type of
prosthesis used. This reduction is mainly due to excess mortality (14 years), while valve-
related events play a minor role (1-2 years). Reoperation for structural valve deterioration
is common in younger patients with tissue valves, causing 4-5% of all deaths for patients
aged 40, depending on the type of tissue valve. On the other hand, younger patients with
mechanical valves have a high lifetime risk of suffering thrombo-embolic and bleeding
events, causing for example 4% of mortality in patients aged 40 years.
Conclusion. Microsimulation allows detailed insight into the factors that affect outcome
after AVR. Valve-related events play a minor but important role, since their effect on life
expectancy can be minimized by choosing the ‘best’ valve substitute for the individual
patient. In this respect microsimulation is a useful and objective decision support tool.
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1077-67 Guideline-Based Standardized Care Substantially 
Reduces Mortality in Medicare Patients With Acute 
Myocardial Infarction: The American College of 
Cardiology’s Guidelines Applied in Practice Program in 
Michigan
Kim A. Eagle, Cecelia K. Montoye, Arthur L. Riba, Anthony C. DeFranco, Robert Parrish, 
Stephen Skorcz, Patricia L. Baker, Benrong Chen, Canopy Roychoudhury, Rajendra H. 
Mehta, University of Michigan, Ann Arbor, MI
Background: It has been shown that the American College of Cardiology (ACC) Guide-
lines Applied in Practice (GAP) program improves adherence to key evidenced-based
therapies in acute myocardial infarction (AMI), particularly when standardized care tools
are used. To assess the impact of GAP on mortality, we studied 30-day and 1-year (yr)
mortality in 2857 Medicare Beneficiaries cared for at 33 hospitals in Michigan during the
3 GAP projects.
Methods: We compared baseline features, in-hospital treatments, and outcomes in 1368
patients cared for prior to GAP and 1489 patients treated after GAP. Logistic regression
models were built to identify clinical variables predictive of 30 day and 1-yr mortality. We
tested effects of the GAP project and the use of standard orders and discharge tool on
mortality.
Results: Pre and post GAP patients were similar in demographics, clinical presentation,
co-morbidities and complications. Multivariate predictors of mortality were old age, heart
failure, increased heart rate, chest pain, atrial fib, MI location, anemia, LVEF, troponin
level, and PCI /CABG: 0.76 C-statistic. Both GAP and use of standardized care tools
were associated with significantly lower 30 day and 1-yr mortality.
Conclusions: The ACC AMI GAP program is associated with a reduced 30-day and 1-yr
mortality among Medicare Beneficiaries. This independent and substantial mortality
reduction is realized in patients who receive system-based care with standard, guideline-
based orders and/or discharge tools. 
1077-68 Decreasing Mortality in Primary Percutaneous Coronary 
Intervention in Northern New England Is Related to 
Efforts at Regional Quality Improvement
Theodore Silver, Mirle Kellett, Jr., Winthrop Piper, Michael Hearne, Peter VerLee, 
Thomas Wharton, John Robb, Matthew Watkins, David Malenka, for the Northern New 
England Cardiovascular Disease Study Group, Dartmouth-Hitchcock Medical Center, 
Lebanon, NH
Background: Primary PCI has become the treatment of choice for STEMI and a focus of
quality improvement efforts (e.g., early recognition, decreased door-to-balloon time) in
Northern New England hospitals. We hypothesized that these efforts would be temporally
associated with lower inhospital mortality for this patient population.
Methods: We studied 3,013 consecutive cases of primary PCI contributed by 8 hospitals
to the Northern New England PCI Registry from 1994 to 2001 to assess changes in
case-mix and inhospital mortality.
Results: Over the study period annual caseload increased from 165 to 535 (Figure).
Case-mix remained stable over time. Crude mortality declined significantly from 6.1% to
3.2% (ptrend=0.01), as did adjusted mortality (ptrend<0.01), and was observed at all
institutions. The declining mortality was seen across patient subsets including those over
age 70 (ptrend=0.02), women (ptrend=0.08), those with left main disease (ptrend=0.01),
and in patients with multivessel disease (p=0.10).
Conclusion: Since 1994 regional mortality associated with primary PCI has decreased
by 48%. While likely multifactorial, it was clearly concurrent with regional efforts at quality
improvement.
1077-69 Underutilization of Effective Treatement in Diabetic 
Patients Admitted With Acute Myocardial Infarction
Dennis T. Ko, Alice M. Newman, Douglas S. Lee, Peter C. Austin, Linda R. Donovan, Jack 
V. Tu, Sunnybrook and Women's College Health Sciences Center, Toronto, ON, Canada, 
Institute for Clinical Evaluative Sciences, Toronto, ON, Canada
Background
Diabetic patients suffering acute myocardial infarction (AMI) have significantly higher
mortality compared with non-diabetic patients. While it has been demonstrated that
thrombolytics are underused in diabetic patients, it is unclear whether other effective
therapies are also underutilized.
Methods 
We analyzed the Enhanced Feedback for Effective Cardiac Treatment (EFFECT) data-
base, an initiative to improve care that collected information for patients admitted with an
AMI in Ontario, Canada during 1999 to 2001.
Results
There were 7,207 AMI patients, 25% had diabetes and 75% did not. Diabetic AMI
patients were significantly older (71 vs 68 years), more likely to be female (41% vs 34%),
had higher likelihood of comorbid conditions, and had higher adjusted mortality at 30-
days (14% vs 11%). Among ideal candidates, aspirin and beta blockers were prescribed
less often both on admission and at discharge in diabetics. However, ACE inhibitors were
prescribed more often compared with non-diabetics at discharge. (Table)
Conclusions
Despite higher risk of death, life-saving therapies such as aspirin and beta blockers are
substantially underutilized in diabetic patients with AMI. Improving the quality of care in
In-hospital, 30 day and 1-year Mortality Rates
GAP No 
GAP
p 
value
Odds Ratio Care 
Tools
No 
Tools
p value Odds Ratio
In 
hospital
10.7% 13.6% 0.017 ------- 8.7% 13.1% 0.0009 ------
30 day 16.7% 21.6% 0.001 1.35 (CI 1.07-1.70) 13.6% 22.4% <0.0001 1.73 (CI 1.27-2.35)
1 year 33.2% 38.3% 0.004 1.28 (CI 1.06-1.56) 29.3% 40.7% <0.0001 1.39 (CI 1.08-1.80)
